Victrelis boceprevir: Phase II started

Merck began the international Phase II DYNAMO 1 trial to evaluate Victrelis boceprevir plus mericitabine and standard of care (SOC, Pegasys pegylated interferon alfa-2a and Copegus ribavirin) in about 25 patients with a null response to previous SOC. ...